Clicky

Ocugen, Inc.(OCGN)

Description: Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company based in Malvern, Pennsylvania.


Keywords: Organ Systems Ophthalmology Eye Vision Diabetic Retinopathy Eye Diseases Retina Blindness Retinopathy Host Disease Graft Versus Host Disease Retinitis Pigmentosa Retinitis Innovative Therapies Ocular Surface Diseases Vision Institute

Home Page: www.ocugen.com

OCGN Technical Analysis

263 Great Valley Parkway
Malvern, PA 19355
United States
Phone: 484 328 4701


Officers

Name Title
Dr. Shankar Musunuri M.B.A., MBA, Ph.D. Co-Founder, Chairman & CEO
Dr. Uday B. Kompella Ph.D. Co-founder & Independent Director
Dr. Vijay Tammara Ph.D. Sr. VP of Regulatory & Quality
Ms. Jessica Crespo CPA, CPA Chief Accounting Officer, Sr. VP of Fin. and VP of Corp. Controller & Treasurer
Dr. Arun Upadhyay Ph.D. Chief Scientific Officer
Ms. Tiffany Hamilton M.B.A. Head of Corp. Communications
Ms. Zara Gaudioso AVP, Head of HR & Chief of Staff
Mr. Michael Shine Sr. VP of Commercial
Dr. Robert J. Hopkins FACP, M.D., M.P.H. Chief Medical Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 15.2207
Trailing PE: 0
Price-to-Book MRQ: 3.6519
Price-to-Sales TTM: 25069.316
IPO Date: 2014-12-03
Fiscal Year End: December
Full Time Employees: 56
Back to stocks